Clear Street, a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, announced the expansion of its equity research offering with the addition of Healthcare, initially focused on the biotechnology sector.
The expanded research offering complements Clear Street’s prime brokerage and clearing solutions for its client base of asset managers, institutions and professional traders across equities, fixed income, derivatives products and markets.
Ed Tilly, President and CEO-Elect of Clear Street said:
“The launch of our Healthcare Equity Research franchise demonstrates our commitment to providing capabilities that align with our clients’ evolving needs. Our expanded equity research service complements our full suite of existing products and allows us to continue providing institutional clients the tools, teams and capabilities they need to navigate global markets and execute successful investment strategies.”
Led by Director of Research Mara Goldstein, the new Healthcare Research franchise provides “in-depth market analysis and investment insights to the firm’s expanding institutional client base.”
To launch coverage, Clear Street has appointed Kaveri Pohlman, Ph.D. and William “Bill” Maughan, Ph.D. as Managing Directors and Senior Equity Analysts, reporting to Ms. Goldstein.
Ms. Goldstein added:
“Fueled by scientific advancements across all fields of medicine, the healthcare sector, particularly biotechnology, has grown immensely and has become a fundamentally important sector of the economy for investors. As the number of biotechnology companies continues to grow, we think it’s important to be a voice in the space, analyzing and highlighting under-followed and under-represented companies that our clients, such as specialist hedge funds and dedicated healthcare fund investors care about.”
Dr. Kaveri Pohlman’s research coverage will reportedly “focus on oncology and autoimmune disease (I&I), spanning multiple technologies, from cell to gene therapy.”
Prior to joining Clear Street, Dr. Pohlman was a Senior Analyst at BTIG where she “covered large and small-cap biotechnology companies.”
Dr. Bill Maughan brings experience in Equity Research across therapeutic areas, and will continue to do so at Clear Street, “including oncology, ophthalmology and genetic medicine, including RNA technologies.”
Prior to joining Clear Street, Dr. Maughan was a Senior Biotechnology Analyst with Canaccord Genuity, “focusing on solid tumor oncology.”
The launch of Healthcare Equity Research enhances Clear Street’s research franchise and complements the company’s product offerings across prime brokerage, professional clearing, futures trading and investment banking services.
The expanding Equity Research offering demonstrates Clear Street’s commitment to key areas “where institutional clients are actively seeking specialized insights.”
The company recently launched Clear Street UK, a pivotal step in building a global, full-service institutional business powered “by cloud-based, financial technology.”
As covered, Clear Street is modernizing the brokerage ecosystem with financial technology and services that empower “market participants with real-time data and products, tools and teams, to navigate capital markets around the world.”
Complemented by white-glove service, Clear Street’s cloud-native, proprietary product suite delivers financing, derivatives, execution and more to power client success, adding “efficiency to the market and enabling clients to minimize risk, redundancy and cost.”
Clear Street’s goal is to create a single platform for “every asset class, in every country and in any currency.”